ChronoScale Corporation Common Stock (CHRN) Expected to Announce Earnings on Monday

ChronoScale Corporation Common Stock (NASDAQ:CHRN) is expected to issue its Q2 2026 resultson Monday, July 27th. Analysts expect ChronoScale Corporation Common Stock to post earnings of ($0.06) per share and revenue of $2.5130 million for the quarter. Individuals can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Monday, July 27, 2026 at 4:30 PM ET.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last released its quarterly earnings data on Tuesday, June 30th. The company reported ($3.89) EPS for the quarter. The business had revenue of $18.09 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. On average, analysts expect ChronoScale Corporation Common Stock to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

ChronoScale Corporation Common Stock Price Performance

CHRN stock opened at $26.43 on Monday. The business has a 50 day moving average price of $19.37 and a 200 day moving average price of $13.38. The company has a quick ratio of 1.03, a current ratio of 1.55 and a debt-to-equity ratio of 0.25. The stock has a market cap of $94.09 million, a price-to-earnings ratio of -4.91 and a beta of 0.99. ChronoScale Corporation Common Stock has a fifty-two week low of $2.91 and a fifty-two week high of $30.00.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC purchased a new position in ChronoScale Corporation Common Stock during the 3rd quarter worth $57,000. Shay Capital LLC acquired a new position in ChronoScale Corporation Common Stock in the third quarter valued at $67,000. Citadel Advisors LLC purchased a new stake in shares of ChronoScale Corporation Common Stock in the third quarter valued at about $198,000. Finally, Geode Capital Management LLC raised its holdings in shares of ChronoScale Corporation Common Stock by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after buying an additional 10,281 shares during the last quarter. Institutional investors and hedge funds own 6.42% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of ChronoScale Corporation Common Stock in a report on Friday, March 27th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $6.00.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.